Moringa Sponsor Disputes New Silexion Conversions, Including $750K at $0.65
SLXN is trading near its 52-week low of $0.373 (7.0% above the low) on light trading volume (0.4× avg).
Summary
Moringa Sponsor, LP disputes four new Silexion debt conversions, including a $750K conversion at $0.65/share, escalating the legal fight over the promissory note.
Key Events · Legal and Risk Events · SLXN
-
New Disputed Conversions
Moringa Sponsor, LP reports four new conversions by Silexion: $29,072 on July 30, $19,187 on July 31, $32,508 on August 5, and $750,001 on August 12, 2026, all disputed as invalid.
-
Deep Discount Conversion
The August 12 conversion of $750,001 into 1,153,848 shares at $0.65 per share is significantly below the current stock price of $0.399, indicating a highly dilutive transaction.
-
Legal Escalation
Moringa Sponsor, LP has filed a claim seeking a declaration that the conversions are void, a determination of an Event of Default, and immediate repayment of the entire outstanding debt.
-
Ownership Dispute
Moringa Sponsor, LP now reports 1,391,790 shares (25% of class), while Moringa Partners Ltd and Ilan Levin report 1,391,827 shares (10.6%), all subject to dispute.
Analysis · SLXN · Life Sciences
Moringa Sponsor, LP has filed an amended 13D disclosing four new debt-to-equity conversions by Silexion Therapeutics, all of which it disputes as invalid. The most significant is a $750,001 conversion on August 12, 2026, at $0.65 per share, which is deeply discounted relative to the current stock price of $0.399. This escalation of the ongoing legal battle over the promissory note could lead to a declaration of default and immediate repayment of the entire outstanding debt, adding significant financial and legal uncertainty for the company.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.37 to $80.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.